Does timing of neoadjuvant chemotherapy influence the prognosis in patients with early triple negative breast cancer?

被引：0
|
作者：
Maria Eleni Hatzipanagiotou
Miriam Pigerl
Michael Gerken
Sophie Räpple
Verena Zeltner
Madeleine Hetterich
Peter Ugocsai
Miriam Fernandez-Pacheco
Elisabeth Christine Inwald
Monika Klinkhammer-Schalke
Olaf Ortmann
Stephan Seitz
机构：
[1] University Medical Centre Regensburg,Department of Gynecology and Obstetrics
[2] University of Regensburg,Tumor Center Regensburg
[3] Bavarian Cancer Registry, Centre for Quality Management and Health Services Research
[4] Regional Centre Regensburg,Department of Gynecology and Obstetrics
[5] Bavarian Health and Food Safety Authority,undefined
[6] Maria Eleni Hatzipanagiotou,undefined
[7] University Medical Centre Regensburg,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷
关键词：
Time to systemic therapy; Triple negative breast cancer; Neoadjuvant chemotherapy; Clinical cancer registry data;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：11941 / 11950
页数：9
相关论文
共 50 条
  • [1] Does timing of neoadjuvant chemotherapy influence the prognosis in patients with early triple negative breast cancer?
    Hatzipanagiotou, Maria Eleni
    Pigerl, Miriam
    Gerken, Michael
    Raepple, Sophie
    Zeltner, Verena
    Hetterich, Madeleine
    Ugocsai, Peter
    Fernandez-Pacheco, Miriam
    Inwald, Elisabeth Christine
    Klinkhammer-Schalke, Monika
    Ortmann, Olaf
    Seitz, Stephan
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (13) : 11941 - 11950
  • [2] Timing of neoadjuvant or adjuvant therapy in patients with early triple negative breast cancer
    Hatzipanagiotou, Maria Eleni
    Pigerl, Miriam
    Gerken, Michael
    Raepple, Sophie
    Zeltner, Verena
    Hetterich, Madeleine
    Ugocsai, Peter
    Inwald, Elisabeth C.
    Klinkhammer-Schalke, Monika
    Seitz, Stephan
    Ortmann, Olaf
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 9 - 9
  • [3] BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
    Tanino, Hirokazu
    Kosaka, Yoshimasa
    Nishimiya, Hiroshi
    Tanaka, Youko
    Minatani, Naoko
    Kikuchi, Mariko
    Shida, Akiko
    Waraya, Mina
    Katoh, Hiroshi
    Enomoto, Takumo
    Sengoku, Norihiko
    Kajita, Sabine
    Hoffman, Robert M.
    Watanabe, Masahiko
    PLOS ONE, 2016, 11 (12):
  • [4] BRCAness and prognosis in triple-negative breast cancer patients treated with neoadjuvant chemotherapy
    Tanino, Hirokazu
    Kosaka, Yoshimasa
    Sengoku, Norihiko
    Waraya, Mina
    Nishimiya, Hiroshi
    Katoh, Hirozhi
    Kikuchi, Mariko
    Minatani, Naoko
    Teraoka, Saeko
    Enomoto, Takumo
    Sato, Takeo
    Masahiko, Masahiko
    CANCER RESEARCH, 2015, 75
  • [5] The response to neoadjuvant chemotherapy and prognosis of triple-negative breast cancer patients.
    Nakano, E.
    Hojo, T.
    Masumura, K.
    Kikuyama, M.
    Akashi, S.
    Kinoshita, T.
    CANCER RESEARCH, 2009, 69 (02) : 337S - 337S
  • [6] Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer?
    Alliot, C
    BRITISH JOURNAL OF CANCER, 2006, 94 (06) : 938 - 939
  • [7] Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer?
    C Alliot
    British Journal of Cancer, 2006, 94 : 938 - 939
  • [8] Response to neoadjuvant chemotherapy in patients with triple negative breast cancer
    Abe, E.
    Hayashi, N.
    Yoshida, A.
    Hamaoka, T.
    Yagata, H.
    Tsugawa, K.
    Tsunoda-Shimizu, H.
    Suzuki, K.
    Nakamura, S.
    CANCER RESEARCH, 2009, 69 (02) : 367S - 367S
  • [9] Neoadjuvant chemotherapy regimens for triple negative breast cancer patients
    Gigolaeva, L.
    Krivorotko, P.
    Zhiltsova, E.
    Dashyan, G.
    Chadjimatova, S.
    Pesotckiy, R.
    Emelyanov, A.
    Semiglazov, V.
    BREAST, 2019, 44 : S70 - S70
  • [10] Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer
    Jiannan Wu
    Shunrong Li
    Weijuan Jia
    Fengxi Su
    Journal of Cancer Research and Clinical Oncology, 2011, 137 : 1505 - 1510
12345